Alzheimer's: New Treatment Idea Targets Tau
A new idea for treating Alzheimer’s disease could eradicate the toxic proteins most closely linked to cognitive decline in the places where they do the most damage, a study from researchers at Columbia University Vagelos College of Physicians and Surgeons suggests.
The study was published online in Science Translational Medicine on May 26.
Early in Alzheimer’s disease, toxic tau proteins accumulate inside the brain’s synapses, compromising the transmission of signals from one neuron to another. Cognitive decline in Alzheimer’s is closely linked to tau: the more tau that accrues, the faster cognition deteriorates.
Eradicating toxic tau could improve cognition in Alzheimer’s patients, and in a previous study, the Columbia team discovered that tau levels can be reduced by enhancing the activity of proteasomes, cell structures that degrade old or unwanted proteins.
“Enhancing proteasome activity improves cognition in mice that make a lot of mutant tau, but we don’t want to boost protein degradation throughout the cell where too much might cause unwanted effects,” says the study’s senior author Natura Myeku, PhD, assistant professor of pathology & cell biology at Columbia University Vagelos College of Physicians and Surgeons.
The new study reveals a potential solution. The most toxic tau proteins, the researchers found, accumulate predominantly on one side of the synapse. And the activity of proteasomes on that side of the synapse can be amplified without affecting proteasomes in other parts of the brain.
Myeku’s team found that a peptide that stimulates PAC1 receptors, which are largely found on the same side of the synapse as tau, reduced toxic tau levels and improved cognitive performance in mice with early-stage tau accumulation. The peptide had little effect on the other side of the synapse.
“Although the peptide is quickly degraded in the body and not a good candidate for therapy in humans,” Myeku says, “we are currently testing another drug, prucalopride, for the same purpose.” Prucalopride, which stimulates a receptor with similar action as PAC1, was recently approved by the FDA for the treatment of gastrointestinal disease.
“By targeting a certain family of receptors that are present mainly on the surface of synapses, our study raises the possibility of a whole new approach to remove toxic proteins in Alzheimer’s and other neurodegenerative diseases, such as Parkinson’s and Huntington’s.” Myeku says.
The study is titled, “PAC1 receptor-mediated clearance of tau in postsynaptic compartments attenuates tau pathology in mouse brain.”
All contributors are: Ari W. Schaler (Columbia), Avery M. Runyan (Columbia), Catherine L. Clelland (Columbia), Eric J. Sydney (Columbia) Stephanie L. Fowler (University College London and UK Dementia Research Institute), Helen Y. Figueroa (Columbia), Seiji Shioda (Hoshi University, Tokyo), Ismael Santa-Maria (Columbia), Karen E. Duff (Columbiaand University College London), and Natura Myeku (Columbia).
The study was funded by grants from the National Institutes of Health (R01AG064244 and K01AG055694), the Alzheimer's Association, the Cure Alzheimer’s Fund, the Brightfocus Foundation, Servier Pharmaceuticals, and the UK Dementia Research Institute (which receives funding from DRI Ltd., funded by the UK Medical Research Council, Alzheimer’s Society, and Alzheimer’s Research UK).
The authors declare that they have no competing interests. Karen E. Duff is a director and scientific board member for Ceracuity LLC.